Drug interactions with itraconazole, fluconazole, and terbinafine and their management

被引:71
作者
Gupta, AK
Katz, HI
Shear, NH
机构
[1] Sunnybrook & Womens Hlth Sci Ctr, Div Dermatol, Dept Med, Toronto, ON, Canada
[2] Univ Toronto, Sch Med, Toronto, ON, Canada
[3] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA
[4] Sunnybrook & Womens Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Toronto, ON, Canada
[5] Sunnybrook & Womens Hlth Sci Ctr, Dept Pharmacol, Toronto, ON, Canada
关键词
D O I
10.1016/S0190-9622(99)70055-1
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A drug interaction develops when the effect of a drug is increased or decreased or when a new effect is produced by the prior, concurrent, or subsequent administration of the other. Before prescribing a drug, it is important to obtain a thorough drug history of the prescription and nonprescription medications taken by the patient. The nonprescription medications may include items such as nutritional supplements and herbal medications. The risk of side effects is an inevitable consequence of drug use. The frequency of adverse reactions is increased in those patients receiving multiple medications. Drug interactions reported in animal or in vitro studies may not necessarily develop in humans. When drug interactions are observed with a particular agent, it cannot be automatically assumed that all closely related drugs will necessarily produce the same interaction. However, caution is advised until sufficient experience accrues. The prescriber should not overestimate or underestimate the potential for a given drug interaction on the basis of personal experience alone. Drug interactions will not necessarily occur in every patient who is given a particular combination of drugs known to produce an interaction. For a clinically significant drug interaction to be manifest, several other factors may be relevant other than just using the two drugs. In many instances drug interactions can be predicted and therefore avoided if the pharmacodynamic effects, the pharmacokinetic properties, and the mechanisms of action of the 2 drugs in question are known. In the case of contraindicated drugs, it may be possible to use an alternative agent.
引用
收藏
页码:237 / 249
页数:13
相关论文
共 222 条
[1]   Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
THERAPEUTIC DRUG MONITORING, 1996, 18 (02) :124-127
[2]   Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (05) :415-419
[3]   The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1996, 10 (03) :314-318
[4]   EFFECT OF ITRACONAZOLE AND TERBINAFINE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MIDAZOLAM IN HEALTHY-VOLUNTEERS [J].
AHONEN, J ;
OLKKOLA, KT ;
NEUVONEN, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) :270-272
[5]   Digoxin-itraconazole interaction: Possible mechanisms [J].
Alderman, CP ;
Allcroft, PD .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (04) :438-440
[6]   DIGOXIN-ITRACONAZOLE INTERACTION [J].
ALDERMAN, CP ;
JERSMANN, HPA .
MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (11-12) :838-839
[7]  
[Anonymous], 1972, J AMER MED ASSOC, V220, P1238
[8]   INDUCTION OF FLUCONAZOLE METABOLISM BY RIFAMPIN - INVIVO STUDY IN HUMANS [J].
APSELOFF, G ;
HILLIGOSS, DM ;
GARDNER, MJ ;
HENRY, EB ;
INSKEEP, PB ;
GERBER, N ;
LAZAR, JD .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :358-361
[9]  
ASSAN R, 1994, DIABETES METAB, V20, P49
[10]   FLUCONAZOLE-WARFARIN INTERACTION [J].
BACIEWICZ, AM ;
MENKE, JJ ;
BOKAR, JA ;
BAUD, EB .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (09) :1111-1111